RDHL · NASDAQ
RedHill Biopharma (RDHL) Stock Price & Fundamentals
RedHill Biopharma (RDHL) closed at $644.33 on Oct 9, 2026, down 0.34% from the previous close of $646.51.
Share price, past year
1Y −13.53%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $644.33 |
| Sep 30, 2026 | $637.14 |
| Aug 31, 2026 | $641.20 |
| Jul 31, 2026 | $624.18 |
| Jun 30, 2026 | $656.58 |
| May 29, 2026 | $658.47 |
| Apr 30, 2026 | $673.73 |
| Mar 31, 2026 | $700.11 |
| Feb 27, 2026 | $703.94 |
| Jan 30, 2026 | $704.33 |
| Dec 31, 2025 | $753.57 |
| Nov 28, 2025 | $730.17 |
| Oct 31, 2025 | $749.13 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- 50.9B
- Dividend yield
- —
- 52-week range
- $612.59 – $761.88
Market cap, P/E and dividend yield aren't shown for RedHill Biopharma yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US.
Financials
RedHill Biopharma reported revenue of $8.04M for fiscal 2024, up 23.17% from fiscal 2023.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2024ended Dec 31, 2024 | $8.04M | +23.2% | — | — | $0.00 | −$9.38M |
| FY2023ended Dec 31, 2023 | $6.53M | −89.4% | — | — | $0.01 | −$35.83M |
| FY2022ended Dec 31, 2022 | $61.80M | −27.9% | — | — | −$0.12 | −$29.38M |
| FY2021ended Dec 31, 2021 | $85.76M | +33.3% | — | — | −$0.21 | −$65.16M |
| FY2020ended Dec 31, 2020 | $64.36M | +923.0% | — | — | −$0.21 | −$48.99M |
| FY2019ended Dec 31, 2019 | $6.29M | −24.8% | — | — | −$0.14 | −$40.92M |
| FY2018ended Dec 31, 2018 | $8.36M | +108.6% | — | — | −$0.17 | −$34.49M |
| FY2017ended Dec 31, 2017 | $4.01M | +3,867.3% | — | — | −$0.26 | −$44.92M |
| FY2016ended Dec 31, 2016 | $101.00K | +3,266.7% | — | — | −$0.24 | −$28.34M |
| FY2015ended Dec 31, 2015 | $3.00K | — | — | — | −$0.19 | −$17.84M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2022ended Jun 30, 2022 | $18.35M | — | −$0.02 |
| Q2 FY2021ended Jun 30, 2021 | $21.50M | — | −$0.06 |
| Q2 FY2020ended Jun 30, 2020 | $20.90M | — | — |
| Q2 FY2019ended Jun 30, 2019 | $1.56M | — | — |
| Q2 FY2018ended Jun 30, 2018 | $2.35M | — | — |
| Q2 FY2017ended Jun 30, 2017 | $483.00K | — | — |
Company profile
- Name
- RedHill Biopharma Ltd.
- Ticker
- RDHL
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 21 Ha'Arba'A Street, Tel Aviv, L3 64739
- Incorporated in
- L3
- SEC CIK
- 0001553846
Recent SEC filings
- Apr 27, 2026
- Apr 10, 2025
- Apr 8, 2024
- Apr 28, 2023
- Mar 17, 2022
- Mar 18, 2021
- Mar 4, 2020
- May 15, 2019
Frequently asked questions
What is RedHill Biopharma's stock price?
RedHill Biopharma (RDHL) closed at $644.33 on Oct 9, 2026, down 0.34% from the previous close of $646.51.
How much revenue does RedHill Biopharma make?
RedHill Biopharma reported revenue of $8.04M for fiscal 2024, up 23.17% from fiscal 2023.
Sources and methodology
Fundamentals come from RedHill Biopharma Ltd.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures